MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CML · Chronic Myelogenous Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
- subtype
- —
- cancer_type
- CML
- ccle_sample_id
- MOLM6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- MOLM-6
- ccle_lineage
- blood
- ccle_lineage_subtype
- CML
- ccle_lineage_sub_subtype
- blast_crisis
- oncotree_code
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.424
- MYC_TARGETS_V2+0.195
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.173
- IL6_JAK_STAT3_SIGNALING+0.163
- IL2_STAT5_SIGNALING+0.118
- INFLAMMATORY_RESPONSE+0.099
- INTERFERON_GAMMA_RESPONSE+0.076
- HEME_METABOLISM+0.039
- COMPLEMENT+0.002
- HYPOXIA-0.023
Top 10 suppressed
- PROTEIN_SECRETION-0.641
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.616
- HEDGEHOG_SIGNALING-0.468
- MITOTIC_SPINDLE-0.454
- TGF_BETA_SIGNALING-0.389
- G2M_CHECKPOINT-0.367
- COAGULATION-0.365
- PANCREAS_BETA_CELLS-0.361
- ANGIOGENESIS-0.355
- UV_RESPONSE_DN-0.354
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ME1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.911 |
| 2 | EOL1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.847 |
| 3 | PLB985_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.846 |
| 4 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.838 |
| 5 | KO52_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.810 |
| 6 | OCIAML3_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.810 |
| 7 | OCIAML5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.802 |
| 8 | MBCproject_0280_T2_RNA | — | D | 0.766 |
| 9 | SRR2016954 | — | — | 0.764 |
| 10 | PL21_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.424 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.195 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.173 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.163 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.118 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.099 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.076 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.039 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.002 | Inavolisib | — uncovered |